Bayer's Kerendia Wins First-Ever US Nod for Type 1 Diabetes Kidney Disease

FDA clears Bayer's Kerendia for chronic kidney disease with type 1 diabetes, a first worldwide; phase III FINE-ONE cut UACR up to 28% at six months.

US regulators have cleared Bayer's kidney drug Kerendia (finerenone) for a patient group that has gone without a fresh treatment option for roughly three decades. The Food and Drug Administration's decision, announced Thursday, extends the medicine's label to adults living with chronic kidney disease alongside type 1 diabetes — a first not just for Bayer, but globally.

The approval rests on the phase III FINE-ONE trial, which enrolled 242 participants and was published in the New England Journal of Medicine in March. Over six months, finerenone cut the urine albumin-to-creatinine ratio (UACR), a key marker of kidney function, by a statistically significant margin versus placebo. The trial reported a 22% reduction at three months and 28% at six months, with a p-value of 0.0001. Depending on how the data are assessed, the six-month improvement is put at between 25% and 34%.

Hyperkalemia emerged as the principal side effect, appearing in 10.1% of treated patients against 3.3% on placebo — roughly ten versus just over three in every hundred. Janet McGill of Washington University underscored how little had changed for these patients over thirty years. The FDA reviewed the application under its priority pathway, a signal of the unmet need the agency sees in this population.

A Third US Label, and a First Worldwide

Kerendia has been available since 2021 for chronic kidney disease in type 2 diabetes, and since 2025 for certain forms of heart failure. The new indication marks the molecule's third US approval — and the first anywhere in the world for this specific group. Between 20% and 30% of Americans with type 1 diabetes go on to develop chronic kidney damage, according to company figures, a cohort that had been poorly served until now.

The commercial stakes are considerable. Bayer has guided toward peak annual sales of more than EUR 3 billion for Kerendia across all indications. Momentum was already building: first-half revenue for the drug jumped 75% to over EUR 600 million, well before this latest expansion. For a company whose pharmaceutical pipeline spent years overshadowed by glyphosate litigation, the approval offers a reminder of where management wants the growth story to sit — alongside, not behind, the agricultural division.

Shares Edge Higher Without Breaking Out

The market's response was measured rather than euphoric. In pre-market Tradegate trading the stock climbed as much as 1.56% to EUR 49.48, before settling around EUR 49.14 to EUR 49.15 — a gain of roughly 0.6% on the prior close of EUR 48.85. A weekly advance of 1.4% frames the move as a continuation of the recent upward drift rather than a one-off spike.

Bayer's market capitalization stands at about EUR 48.46 billion. The shares remain some 8.8% below their 52-week high of EUR 53.86, touched in early July, while sitting comfortably above the 200-day moving average of EUR 42.39. Year to date, the equity has added roughly a third of its value, reflecting an improved news flow even as the Roundup overhang continues to hum in the background.

For investors, the Kerendia label expansion is chiefly a medium-term argument: it widens the drug's addressable market and reinforces Bayer's ambition to make pharmaceuticals a dependable growth engine. The question now is whether that momentum shows up in concrete revenue gains when the next quarterly figures land.